Beth L Brogan

Vanderbilt University, Nashville, MI, USA

Are you Beth L Brogan?

Claim your profile

Publications (2)8.3 Total impact

  • Article: Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series.
    [show abstract] [hide abstract]
    ABSTRACT: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. We conducted a retrospective case series of 3 patients with primary LBCL of the leg. The 3 elderly patients presented with progressive erythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20(+)). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.
    Journal of the American Academy of Dermatology 09/2003; 49(2):223-8. · 3.99 Impact Factor
  • Article: Drug-induced rheumatic syndromes.
    Beth L Brogan, Nancy J Olsen
    [show abstract] [hide abstract]
    ABSTRACT: Rheumatic syndromes related to drug therapies have been described for decades. The introduction of many new therapeutic agents in recent years has been accompanied by an increase in such reported associations. By definition, drug-induced syndromes are temporally related to starting a drug, and the symptoms and signs generally regress with its discontinuation. The classic and still most common cases resemble systemic lupus erythematosus or scleroderma. Some newer agents appear related to myositis or vasculitis. The origins of most of these syndromes remain obscure.
    Current Opinion in Rheumatology 02/2003; 15(1):76-80. · 4.31 Impact Factor